Editas Medicine (EDIT) Profit After Tax (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Profit After Tax data on file, last reported at -$25.1 million in Q3 2025.

• On a quarterly basis, Profit After Tax rose 59.58% year-over-year to -$25.1 million in Q3 2025; TTM through Sep 2025 was -$199.8 million, a 5.1% increase from a year earlier, with the FY2024 full-year figure at -$237.1 million, down 54.74% from the prior year.
• Profit After Tax for Q3 2025 stood at -$25.1 million, up from -$53.2 million in the prior quarter.
• Over the last five years, Profit After Tax for EDIT reached as high as -$18.9 million in Q4 2023 and fell as low as -$76.1 million in Q1 2025.
• Historically, Profit After Tax has averaged -$50.4 million across 5 years, with a median of -$53.2 million in 2025.
• Across the five-year window, Profit After Tax tumbled 599.83% in 2021 and surged 68.93% in 2023, its largest moves.
• Year by year, Profit After Tax stood at -$41.4 million in 2021, then plunged by 46.58% to -$60.7 million in 2022, then jumped by 68.93% to -$18.9 million in 2023, then tumbled by 140.52% to -$45.4 million in 2024, then jumped by 44.67% to -$25.1 million in 2025.
• Per Business Quant data, the three most recent Profit After Tax figures were -$25.1 million in Q3 2025, -$53.2 million in Q2 2025, and -$76.1 million in Q1 2025.